WP
GRNA

Woodline Partners’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Woodline Partners’s Portfolio GRNA Stock Details GRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-450,000
Closed -$4.46M – 867
2021
Q4 		$4.46M Hold
450,000
– – 0.06% 297
2021
Q3 		$4.45M Buy
+450,000
New +$4.41M 0.07% 271

Other funds holding GRNA

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VS
VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return
CGC
Continental Grain Company New York $366M AUM 0.18% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $119M AUM 87.46% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCMH
Oxbow Capital Management (HK) Hong Kong $371M AUM 383.45% 1-Year Est. Return

Woodline Partners's GRNA Position: Q1 2022 in Review

Woodline Partners sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q1 2022, closing a stake of 450,000 shares — an estimated $4.46M sold.

Woodline Partners first reported a position in GRNA in Q3 2021 and held it in 2 quarters. The position peaked at $4.46M in Q4 2021. 39 funds tracked by Wall St. Rank hold GRNA as of Q1 2022.

  • Woodline Partners reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q1 2022 after selling out during the quarter.
  • Woodline Partners sold 450,000 GreenLight Biosciences Holdings, PBC Common Stock shares in Q1 2022, an estimated $4.46M.
  • Woodline Partners first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q3 2021 and held it in 2 quarters.
  • Woodline Partners's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $4.46M in Q4 2021.
  • 39 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q1 2022.

Based on Woodline Partners's 13F filing for Q1 2022, filed 16 May 2022.